Sarepta Therapeutics, Inc. (SRPT)

NMS – Real Time Price. Currency in USD

16.85

+0.83 (5.18%)

At close: Jun 26, 2026, 4:00 PM EDT

16.86

+0.01 (0.04%)

After-hours: Jun 26, 2026, 7:59 PM EDT

08.06.2026

Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

08.06.2026

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

05.06.2026

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

04.06.2026

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

01.06.2026

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i.

13.05.2026

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presen.

Videos

29.07.2025

Positive

SRPT Rallies on FDA Green Light: A New Bottom for the Stock?

29.07.2025

Positive

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

25.07.2025

Neutral

Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech

21.07.2025

Negative

HC Wainwright's Kapoor talks if Sarepta shares could hit $0

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
SRPT	Barclays	Equal Weight	undefined >> $22	July 29th 2025
SRPT	Bernstein	Market Perform	undefined >> $13	July 29th 2025
SRPT	H.C. Wainwright	Sell	undefined >> $5	July 29th 2025
SRPT	Oppenheimer	Outperform	undefined >> $37	July 29th 2025
SRPT	JP Morgan	Neutral	undefined >> $24	July 29th 2025
SRPT	Barclays	Underweight	undefined >> $10	July 28th 2025
SRPT	JP Morgan	Underweight	undefined >> undefined	July 25th 2025
SRPT	Citigroup	Sell	undefined >> $7	July 24th 2025

Press releases

06.05.2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.

31.03.2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.

25.03.2026

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerab.

24.03.2026

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under th.

Sarepta Therapeutics, Inc. (SRPT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

Sarepta Therapeutics to Participate in Upcoming Investor Conferences